Advances in medical sciences · 2026
Selected risk factors for mortality in children with HUS - a single-center analysis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jarosz-Wójcik Ewelina, Zajączkowski Mateusz, Drożdż Dorota, Błasiak Magdalena, Miklaszewska Monika
Аннотация
PURPOSE: The aim of the study was to describe clinical and laboratory characteristics of hemolytic-uremic syndrome (HUS), and identify prognostic factors, including risk factors for mortality and complications.
MATERIALS AND METHODS: It is a retrospective study of 74 pediatric patients (69 survivors and 5 non-survivors) with the first episode of HUS who were hospitalized in our tertiary reference center during 10-year period.
RESULTS: Compared to survivors, non-survivors significantly more frequently developed neurological symptoms (100% vs. 31.9%), suffered from respiratory tract infections (80% vs. 27.5%), respiratory insufficiency (100% vs. 21.7%), circulatory failure (80% vs. 2.9%), and more often required renal replacement therapy (100% vs. 52.2%). In this group, there was a significant reduction in complement C3c and C4 components (0.67 vs. 0.97, 0.08 vs. 0.18, respectively). Elevated PCT, CRP, D-dimers, APTT, lipase, AST, GGTP and reduced C3c and C4 were associated with increased mortality risk. Severe neurological and ophthalmological complications, as well as circulatory insufficiency were the strongest predictors of death. Overall mortality rate was 6.8%.
CONCLUSIONS: Neurological (ischemic stroke, ophthalmological anomalies) and systemic (circulatory failure) complications may represent important determinants of outcome in pediatric HUS. Mortality also appears to be associated with systemic inflammatory activation and coagulopathy.
MATERIALS AND METHODS: It is a retrospective study of 74 pediatric patients (69 survivors and 5 non-survivors) with the first episode of HUS who were hospitalized in our tertiary reference center during 10-year period.
RESULTS: Compared to survivors, non-survivors significantly more frequently developed neurological symptoms (100% vs. 31.9%), suffered from respiratory tract infections (80% vs. 27.5%), respiratory insufficiency (100% vs. 21.7%), circulatory failure (80% vs. 2.9%), and more often required renal replacement therapy (100% vs. 52.2%). In this group, there was a significant reduction in complement C3c and C4 components (0.67 vs. 0.97, 0.08 vs. 0.18, respectively). Elevated PCT, CRP, D-dimers, APTT, lipase, AST, GGTP and reduced C3c and C4 were associated with increased mortality risk. Severe neurological and ophthalmological complications, as well as circulatory insufficiency were the strongest predictors of death. Overall mortality rate was 6.8%.
CONCLUSIONS: Neurological (ischemic stroke, ophthalmological anomalies) and systemic (circulatory failure) complications may represent important determinants of outcome in pediatric HUS. Mortality also appears to be associated with systemic inflammatory activation and coagulopathy.